Drug Profile
Roblitinib - EverNov
Alternative Names: EVER-4010001; FGF 401; NVP-FGF401Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer EverNov; Novartis Oncology
- Class Amides; Antineoplastics; Naphthyridines; Piperazines; Pyridines; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer; Solid tumours
Most Recent Events
- 22 Aug 2023 Everest Medicines expects approval of NDA or BLA for Roblitinib in Liver cancer in 2025 and beyond (Everest Medicines pipeline, August 2023)
- 22 Mar 2021 EverNov plans a phase II trial for Liver cancer in China in the second half of 2021
- 09 Mar 2021 Phase-I/II development is ongoing in China, Italy, South Korea (PO) for Solid tumours and Liver cancer